Steris (STE) – Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Steris (NYSE: STE) recently:

  • 2/8/2018 – Steris had its “buy” rating reaffirmed by analysts at KeyCorp. They now have a $103.00 price target on the stock.
  • 2/8/2018 – Steris was given a new $102.00 price target on by analysts at Northcoast Research. They now have a “buy” rating on the stock.
  • 1/24/2018 – Steris was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “STERIS has been witnessing strong organic growth across Specialty Services, Life Sciences and Applied Sterilization segments. Moreover, gross and operating margins have been improving year over year. Recently, the company made a couple of organizational changes, expected to serve its customers in a better way. We also expect this move to enhance the company’s cost structure. Further, growth in free cash flow is indicative of the company’s strong cash balance. On the flip side, STERIS may incur sales loss owing to business divestments in the coming quarters. STERIS operates in a tough competitive landscape. Also, currency headwinds continue to pose concerns for the company. Over the past three months, STERIS has been trading below the broader industry.”
  • 1/23/2018 – Steris was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $103.00 price target on the stock. According to Zacks, “STERIS has been witnessing strong organic growth across Specialty Services, Life Sciences and Applied Sterilization segments. Moreover, gross and operating margins have been improving year over year. Recently, the company made a couple of organizational changes, expected to serve its customers in a better way. We also expect this move to enhance the company’s cost structure. Further, growth in free cash flow is indicative of the company’s strong cash balance. On the flip side, STERIS operates in a tough competitive landscape. Also, currency headwinds continue to pose concerns for the company. Moreover, STERIS witnessing a year-over-year decline in revenues in the last reported quarter was a disappointment. Also, over the past three months, STERIS has been trading below the broader industry.”
  • 1/3/2018 – Steris had its “market perform” rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $100.00 price target on the stock.
  • 12/29/2017 – Steris was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “STERIS operates in a tough competitive landscape. Also, currency headwinds continue to pose concerns for the company. Moreover, STERIS witnessing a year-over-year decline in revenues in the last reported quarter was a disappointment. On a positive note, over the past three months, the company has been trading above the broader industry. STERIS has been witnessing strong organic growth across Specialty Services, Life Sciences and Applied Sterilization segments. Moreover, gross and operating margins have been improving year over year. Recently, the company made a couple of organizational changes, expected to serve its customers in a better way. We also expect this move to enhance the company’s cost structure. Further, growth in free cash flow is indicative of the company’s strong cash balance.”

Shares of Steris PLC (STE) traded down $0.15 on Monday, hitting $85.42. The stock had a trading volume of 93,370 shares, compared to its average volume of 382,287. Steris PLC has a 1 year low of $67.00 and a 1 year high of $93.71. The company has a quick ratio of 2.22, a current ratio of 2.82 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $7,260.45, a P/E ratio of 29.97 and a beta of 1.22.

Steris (NYSE:STE) last issued its earnings results on Wednesday, February 7th. The medical equipment provider reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.07 by $0.05. The firm had revenue of $661.90 million for the quarter, compared to the consensus estimate of $663.17 million. Steris had a return on equity of 11.57% and a net margin of 9.42%. The company’s revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.98 earnings per share. equities research analysts expect that Steris PLC will post 4.13 EPS for the current fiscal year.

In other Steris news, VP John Adam Zangerle sold 3,650 shares of the stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $88.00, for a total transaction of $321,200.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Sudhir K. Pahwa sold 2,000 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $92.09, for a total value of $184,180.00. The disclosure for this sale can be found here. Corporate insiders own 2.55% of the company’s stock.

STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.

Receive News & Ratings for Steris PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply